5-羟色胺2C受体作为精神分裂症治疗靶点的研究进展

Progress in 5-HT2C receptor as a therapeutic target for treatment of schizophrenia

随着第2代抗精神病药物引起体质量增加和心血管不良反应的报道越来越多,研究者近年来开始将关注点投向治疗精神分裂的新靶点——5-羟色胺2C受体(5-HT2C受体)。一方面,有研究表明激动5-HT2C受体具有降低黑质纹状体多巴胺的作用,推测其潜在的抗精神病作用;另一方面,第2代抗精神病药物对5-HT2C受体的拮抗作用是其引起患者体质量增加的重要因素,反之激动5-HT2C受体则可能具有降低体质量的效应。该文以文献综述的形式就5-HT2C受体的抗精神病效应和与之相关的体质量增加不良反应进行阐述。

With an increasing number of reports on side effects including antipsychotic induced weight gain and cardiovascular risks,interest of the researchers has been transferred to a new target for the treatment of schizophrenia—serotonin 2C receptor（5-HT2C receptor）.On one hand,activation on 5-HT2C receptors can lead to decrease of dopamine in the nigrostriatum,which presents its potential antipsychotic effect;on the other hand,the secondgeneration of antipsychotics＇ antagonism on the 5-HT2C receptors is an important factor of patients＇ weight gain.Conversely,agonism on the 5-HT2C receptors may result in weight loss efficacy.This paper introduced the potential therapeutical effect of 5-HT2C receptor on schizophrenia and the relation between the receptor and correlated weight gain.